# Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients

> **NCT02431351** · PHASE2 · WITHDRAWN · sponsor: **Karyopharm Therapeutics Inc**

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT02431351
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2017-12
- **Final completion:** 2019-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial never opened.
- **Last updated:** 2023-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431351, "Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT02431351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*